Why the study?
Does intravenous furosemide plus small-volume hypertonic saline solutions improve serum markers of heart failure?
Does intravenous furosemide plus small-volume hypertonic saline solutions improve serum markers of heart failure?
Answers are grounded in this paper and cite their sources.
The addition of small-volume hypertonic saline to intravenous furosemide may offer therapeutic benefits in heart failure beyond simple congestion relief by modulating stretching and fibrosis mechanisms.
Our findings concerning a comparable degree of reduction in the serum levels of three cardinal biomarkers indicate that a reduction in serum heart failure markers is not linked to the higher degree of congestion relief with a more rapid achievement of a clinical compensation state. This issue may have possible benefits on clinical practice concerning its therapeutic effects over and beyond the simple amelioration of clinical congestion signs and symptoms. Nevertheless, our findings of higher delta values after treatment with i.v. furosemide plus HSS indicate a possible higher efficacy by means of modulation of the stretching and fibrosis mechanisms.
No takes yet. Share an insight, caveat, or question.
Tuttolomondo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: